Readmore: Local, Health, Education, Community, Economy, News, Science, Technology, MS, Multiple Sclerosis, People Living with MS, Walk to End MS, Superior Dome, Fight MS, Marquette, Cause, Community Outreach

MARQUETTE -- Dozens who helped an important cause in Marquette this Sunday didn't have to worry about the rain in order to do so. They did it all inside the Superior Dome.

This is the first walk the regional Multiple Sclerosis organization has done in a few years. The walk for Multiple Sclerosis is part of a national push that supports cutting edge research and providing services to help people with MS move their lives forward.

"The money for this walk and for MS in general is very important for research and hopefully to find a cure," said Lisa Taylor, an organizer and head of the local support group in Marquette.

"And it goes to people who can't afford medication, or people who need walkers or canes or wheelchairs."

To find out more about their cause, click here.

More:
Dozens walk to support Multiple Sclerosis cause

By Irene Maher, Times Staff Writer Irene MaherTampa Bay Times In Print: Monday, September 17, 2012

Regardless of your political leanings, at least one group of Americans was grateful for the Republican and Democratic National Conventions: Those affected by MS.

People with multiple sclerosis appreciated the shout-out from Ann Romney, wife of presidential nominee Mitt Romney, at the Republican National Convention in Tampa and from first lady Michelle Obama with the Democrats a week later in Charlotte, N.C.

Romney has been living with MS since 1998. Obama's father lived with the disease for about 30 years before his death at age 66. Both women related how their lives were affected by MS.

That kind of exposure does more than increase awareness of an often misunderstood disease that afflicts 400,000 Americans, experts said.

"In the case of Ann Romney, seeing someone at the podium, in the national spotlight, living an obviously busy, active life allows others to see how much you can accomplish with MS," said Dr. Stanley Krolczyk, director of the multiple sclerosis division in the department of neurology at USF Health. "It puts a different face on the disease when celebrities, like Montel Williams and Clay Walker, for example, go public and talk about living with MS."

Jzon Livingston Sr., a patient of Krolczyk's, agrees. The 33-year-old self-employed IT administrator was diagnosed with MS four years ago. With treatment, he's been able to continue working and keep up with his three children, ages 15, 13 and 11. Livingston was moved when Obama described watching the decline in her father.

"That's what the average person needs to know about MS. It's a hard disease to have," he said. "Without knowledge of how it can affect lives, there's no understanding. Without understanding, there's no action."

Multiple sclerosis is a chronic disease of the central nervous system that targets the brain, spinal cord and optic nerves. It can range from mild to severe, where the patient is paralyzed or blind. The disease is unpredictable, and symptoms may start suddenly and persist, then resolve. Sometimes, it seems to be dormant and patients may go months or years without a flare-up. Others, though, have symptoms all the time.

View post:
Multiple sclerosis patients, doctors appreciate help from Ann Romney, Michelle Obama

Twin Falls, Idaho (KMVT-TV) Tammy Lynard of Filer was diagnosed with multiple sclerosis seven years ago.

She says her brain sends messages that her muscles don't always get. She tires easily and the heat bothers her. Lynard takes a shot every day, but she wants to help find a cure for MS.

Lynard says, "It was kind of a shock when you first hear about it. You try to get as much information as possible. You see the neurologist, they get you on therapies, hopefully as soon as possible. Hopefully the therapies help you live a better life."

Like any other medical condition, MS can affect different people to different degrees. Lynard says one out of every 300 people in idaho have multiple sclerosis.

Lynard says, "The MS Society is great with information, they tell you how to get involved, what to do. I heard about the Walk that first year, and I met a lot of people. I found out there's a lot of people in this area that have the disease. In fact, we're one of the highest in the nation."

You can sign up for Saturday's "Walk MS" in Twin Falls online at walkmsidaho.org , or you can call 1 (800) FIGHT MS, and select option two.

Walk MS will be held this Saturday at the Twin Falls Visitor Center near the Perrine Bridge. Registration starts this Saturday at 8:30 a.m., and the walk begins at ten o'clock.

Walk MS is free to participate in, but the organizers encourage you to raise some money to benefit the cause.

Sept. 19, 2012.

Go here to see the original:
Local Woman Joins Battle Against Multiple Sclerosis

By Liz Farmer

A scholarship supported by University of Texas football legend Earl Campbell and his son Tyler Campbell could make it easier for students affected by multiple sclerosis to finish college.

Earl Campbell, NFL Hall of Fame running back and Heisman Trophy winner, announced Tuesday that he and his son have raised $60,000 for the nonprofit National Multiple Sclerosis Society to provide scholarships for college students who have MS or who have a parent with MS. The society reports it has awarded $187,000 in scholarships to 22 Texas students this year.

MS is a chronic disease of the central nervous system that interrupts information flow between the body and the brain with symptoms including limb numbness, paralysis and vision loss. Campbell's son was diagnosed with MS while at San Diego State University.

The Campbells raised part of the scholarship funds through sales of "The Unstoppable Earl Campbell," a Warner Bros. piece of art signed by Earl Campbell that depicts him in UT gear running a football past cartoon characters including Bugs Bunny and Yosemite Sam.

"I feel very happy that my son and our family has done something to give back," Earl Campbell said. Some money came from benefits such as the Flavors of Austin, which featured local food and drinks. Tyler Campbell said raising money for scholarships is great but he's not satisfied.

"We have to put this disease to rest," he said.

Scholarship recipient Justin Williams is studying for a degree in neurobiology at UT and said he wants to treat people such as his grandmother and father, who both have MS. "My dad's doctor made me truly believe a doctor could change someone's life," Williams said. "I can't thank Earl and Tyler enough."

Bridgette Kieffer, who also got a scholarship, said her mother was diagnosed with MS a few months before she was born. Kieffer said she is pursuing a degree in sociology and English.

"I knew that (college) may not be a possibility because of the cost of medical bills," Kieffer said. "The scholarship has given my family hope and showed us that there's more to life."

Continued here:
Former Longhorn Earl Campbell gives donation to National Multiple Sclerosis Society

A new oral medication to treat patients in the early stages of multiple sclerosis has shown considerable promise in two clinical trials, researchers announced Wednesday.

The medication is on track to become just the third oral drug available to MS patients, and potentially the safest and most effective, experts said. The second oral drug, called Aubagio, was approved just last week.

MS was virtually untreatable only two decades ago, but today nine "disease modifying" drugs are available for early-stage patients; a half-dozen more are in the late stages of development. Most patients in the early stage of the disease, a form called relapsing-remitting MS, take drugs intravenously.

The two new studies, published online in The New England Journal of Medicine, found that the drug BG-12, developed by Biogen Idec, reduced relapse rates in patients with relapsing MS by about 50 percent.

The drug also significantly reduced the frequency of new brain lesions often associated with these attacks, and slowed the progression of disease compared with a placebo.

The studies were Phase 3 trials, a last step on the road to drug approval. The Food and Drug Administration is required to make a decision about the drug's approval before the end of this year.

"This drug is clearly quite effective in managing disease and reducing disability, and the safety profile looks quite good," said Timothy Coetzee, the chief research officer at the

Multiple sclerosis is often a progressive disease in which the immune system damages neurons in the brain and spinal cord.

A majority of people with MS have relapsing-remitting MS, characterized by flare-ups that cause lesions in the brain to develop and neurological symptoms to emerge or worsen. Eventually, more than half of patients develop a progressive form of MS, leading to permanent disabilities.

Interferons, the drugs most commonly used in relapsing MS, reduce relapses by about 30 percent, and have not been shown to slow the progression of the disease and disability. The newly approved Aubagio also reduces relapses by about 30 percent, and it has the advantage of being an oral drug.

Read this article:
Pill shows promise in suppressing multiple sclerosis relapses

European Multiple Sclerosis Platform is looking for an intern

The Brussels-based European Multiple Sclerosis Platform (EMSP) is looking for a full-time, paid internship to support the organisation from September 2012 onwards in its Public Affairs and Communications efforts. The envisaged duration of the internship is 6 months, with a possible 3-month extension. The intern will provide support on flagship projects of the EMSP (e.g. further development of our YOUTH project) and contribute to the EMSP's website / web alert as key external communication tools.

Profilea background in communication or EU studies outstanding communication skills and excellent English excellent drafting skills; track-record in contributing to print and online publications a good understanding of European policies and the workings of the EU institutions

Interpersonal skills flexible, can-do attitude well-organised team player yet autonomous

Qualified candidates should submit their CV and cover letter in English to the attention of Christoph Thalheim, Deputy CEO and Director of External Affairs at christoph.thalheim@emsp.org. by the 25th September at the latest. Please note that only short listed candidates will be contacted.

About EMSP The EMSP is representing the interests of 38 national MS societies /patient organisations at the European level, working towards equitable treatment and support for persons with MS throughout Europe. Multiple Sclerosis is the most common debilitating neurological disease of young and middle aged people in Europe. More than 600,000 Europeans are affected.

2012 European voice. All rights reserved.

See the original post here:
Intern - European Multiple Sclerosis Platform

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/k4b4f3/global_multiple_sc) has announced the addition of the "Global Multiple Sclerosis Drug Pipeline Capsule - 2012" report to their offering.

This report is an outline of all the key research and development (R&D) activities of the global Multiple Sclerosis drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the Multiple Sclerosis drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:

- Multiple Sclerosis: Overview

- Multiple Sclerosis Drug Pipeline Overview

- Multiple Sclerosis Phase 3 Clinical Trial Drug Pipeline Insights

- Multiple Sclerosis Phase 2 Clinical Trial Drug Pipeline Insights

See the original post here:
Research and Markets: Global Multiple Sclerosis Drug Pipeline Capsule - 2012

Sanofi SA has won U.S. approval for its multiple sclerosis pill Aubagio - one of the two treatments for the chronic disease that could return the French drugmaker to growth after several blockbuster drugs lost patent protection.

The drug has been shown to be less effective than some rivals but has milder side effects and analysts say it could find favor among newly diagnosed patients. Around 35 percent to 40 percent of multiple sclerosis (MS) sufferers prefer to take no medication rather than face unwanted side effects.

"In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo," Russell Katz, director of the Division of Neurology Products at the Food and Drug Administration, said in a statement on Wednesday.

Aubagio is expected to launch on the U.S. market in a few weeks, a spokeswoman for Sanofi unit Genzyme said.

Multiple sclerosis, which has no cure, affects 2.5 million people worldwide. It is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision.

MS drugs Gilenya by Novartis and Biogen Idec Inc's BG-12 are expected to dominate a market that JPMorgan analysts predict growing to $14 billion in 2015 from $9.6 billion last year.

Aubagio is seen grabbing a much smaller chunk of this market, reaching modest sales of $353 million in the United States and five major European countries by 2020, according to business intelligence firm Datamonitor.

Cheuvreux analyst Marcel Brand, who has a more optimistic forecast, predicts peak sales of Aubagio of 1.48 billion euros by 2018. "Although Aubagio is not as effective on relapse rates as Gilenya, it's free of its longer-term side effects," he said.

Patients taking Gilenya have to be monitored because the drug causes the heart rate to slow down in the first hours after ingestion.

European regulators are expected to give their response to Aubagio in the first quarter of 2013.

Here is the original post:
Sanofi multiple sclerosis pill gets US approval

The U.S. FDA this week approved a once-a-day pill for the treatment of multiple sclerosis (MS). The pill, being branded as Aubagio by Sanofi S.A., is specifically for the treatment of adults with relapsing forms of MS.

In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo, said Dr. Russell Katz, director of the division of neurology products in the FDAs Center for Drug Evaluation and Research. Multiple sclerosis can impair movement, sensation, and thinking, so it is important to have a variety of treatment options available to patients.

According to the National Institutes of Health, MS is a chronic autoimmune disease that affects the central nervous system. It disrupts the communication between the brain and the body, causing motor skill disruption for nearly every part of the body, depending on which nerves in the brain are damaged.

As for the drug itself, side effects seen during drug trials included diarrhea, abnormal liver tests, nausea, and hair loss. Also, the box warnings for the drug warn of possible liver problems and fetal harm, including the risk of birth defects. Doctors will have to check patients liver function and give a pregnancy test before starting treatment with Aubagio.

Many people living with MS struggle with the additional burden of injectable therapies administered daily to weekly, said Dr. Aaron Miller, medical director at the center for multiple sclerosis at Mount Sinai Medical Center. The FDAs approval of Aubagio, a new oral treatment option, is an encouraging advancement for the MS community and may be a valuable treatment for people living with this often debilitating disease.

Go here to read the rest:
Multiple Sclerosis Pill Approved by U.S. FDA

Editor's Choice Main Category: Multiple Sclerosis Also Included In: Regulatory Affairs / Drug Approvals Article Date: 15 Sep 2012 - 0:00 PDT

Current ratings for: Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA

1.5 (2 votes)

According to experts, the Multiple Sclerosis prescribing market is worth $12 billion annually. If Aubagio becomes popular, it has the potential to become a major earner for its makers, Sanofi-Aventis. However, it is entering a highly-competitive market with very effective existing medications. Novartis' Gilenya and Tysabri from Elan Corp are said to be more effective than teriflunomide.

Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said:

Multiple sclerosis is a long-term autoimmune, inflammatory disease of the central nervous system. Communication between the brain and other parts of the body are disrupted. Multiple Sclerosis is one of the most common causes of neurological disability in young adults. Twice as many females live with MS than males.

People with MS have episodes of relapses (worsening function), followed by remissions (recovery). Eventually, remission periods may be incomplete as the disease progresses. Aubagio has been approved for the initial phases of the disease.

According to clinical trial results, the following side effects among people taking Aubagio were reported: hair loss, nausea, abnormal liver test results, and diarrhea.

Aubagio contains a Boxed Warning explaining to doctors and their patients that there is a risk of liver problems, which may sometimes be fatal, as well as birth defects. Doctors should carry out blood tests beforehand to make sure liver function is normal. During treatment with Aubagio, liver functions tests should be performed periodically.

The Boxed Warning also alerts prescribers and their patients about some animal studies which linked the drug with a higher risk of fetal harm. That is why Aubagio is labeled as a Pregnancy Category X drug, meaning that female patients of childbearing age should have negative pregnancy test results (and use effective birth control therapy) before being considered for Aubagio treatment.

Read the original:
Aubagio (teriflunomide) Approved For Multiple Sclerosis Treatment, FDA

By Matt McMillen WebMD Health News

Reviewed by Laura J. Martin, MD

Sept. 13, 2012 -- The FDA has approved Aubagio (teriflunomide), a new drug for the treatment of multiple sclerosis (MS). The once-a-day tablet will be prescribed to adults with relapsing forms of the chronic, incurable disease.

In a two-year study, the Aubagio reduced yearly relapses by nearly a third compared to placebo. It also slowed the progression of the disease.

"We are greatly encouraged to see a new oral therapeutic option become available to people living with MS," said Timothy Coetzee, PhD, chief research officer at the National MS Society, in a news release issued by the drug's developer, Genzyme.

MS is the most common disabling neurological disease among young adults, according to the National Institute of Neurological Disorders and Stroke. About 400,000 people in the U.S. have MS. As many as two-thirds of them are women. The disease is usually diagnosed between the ages of 20 and 50.

MS often gradually worsens over time. It causes fatigue, pain, vision and muscle problems, and other difficulties.

Aubagio does not come without risks. The drug's label will include a boxed warning that alerts to the risk of potentially fatal liver problems. The label advises that patients' liver function should be tested before starting Aubagio and while on the drug.

The box warning also mentions the risk of birth defects. Women should not be pregnant when they start the drug and must use birth control while taking it.

Other possible side effects include diarrhea, abnormal liver tests, nausea, and hair loss.

Visit link:
FDA Approves New Multiple Sclerosis Drug Aubagio

Multiple sclerosis (MS) is an autoimmune disease that affects approximately 400,000 people in the United States. Caused by damage to the myelin sheath the protective coating of the nerves in the brain MS is marked by an array of symptoms, including muscle spasms, loss of vision and difficulty moving arms and legs.

While there is no cure for MS, there are various treatments available for those suffering from the disease. Dr. Michael Devereaux, a neurologist for University Hospitals Case Medical Center, spoke with FoxNews.com about the many options for MS patients looking for symptom relief. According to him, there are two main goals when it comes to treating MS.

One is treating the acute attacks, Devereaux said. And then, what youre really interested in even more is reducing the frequency of attacks and reducing overall disability over time. Thats been a harder to question to answer from studies and the like, because all the drugs are promoting the idea that they can reduce frequency and overall disability, but theres been some debate about that.

Modifying the disease

During MS, white blood cells, called T-cells, become activated and cross the blood-brain barrier into the brain. While there, they cause an inflammatory response, ultimately damaging the myelin sheath and destroying the axons of the nerves.

Various drugs, called immunologeratory agents, have been developed to dampen the inflammatory response for those with relapsing-remitting MS. The main injectable drugs include beta interferons (Avonex, Betaseron, Extavia), glatiramer acetate (Copaxone), and the somewhat controversial drug, natalizumab (Tysabri)

Tysabri has been in the news a lot because it led to breakouts of another condition progressive multifocal encephalopathy (PML), Devereaux said. Its a very small percentage of cases. Its often given to people not doing well. Its highly effective, but it has this significant, but small, real risk.

The last agent is an oral agent called fingolimod (Gilenya), and is the most convenient for patients, according to Devereaux.

Treating MS attacks

MS is marked by periods of remission, alternating with periods of mild to severe exacerbations. While the agents are used to prevent these flare-ups, there are also treatment options for when exacerbations do occur. The main treatment is to give patients a high dose of glucocorticosteroids

Read more here:
Current treatment options for multiple sclerosis

Posted on: 7:20 pm, August 31, 2012, by Kelley Hoskins, updated on: 07:14pm, August 31, 2012

ST. LOUIS (KPLR)-A diagnosis of multiple sclerosis doesnt happen to just one person, it affects the whole family. Its a life long disease , and an unpredictable We take a closer look a two ordinary people dealing with life and the ups and downs of the disease. Two very different people with two very different life styles. MS affects the ability of nerve cells in the brain and spinal cord to communicate with each other effectively

One is aprominent St. Louis Pastor the other a local nurse . But what they do have is in common they both are battling multiple sclerosis. Pastor Charles Roach is very active at Trinity Mount Carmel Baptist Church in St. Louis County .He also served his country in the United States Air Force as Staff Sergeant.

Each and every Sunday he delivers a powerful message to his congregation. Pastor Roach says multiple sclerosis runs in his family and he wants to empower , equip and educate others about the disease. Its important that all of us to share an experience of some types of difficulty . It may not be physical as mine but it could be mental or emotional . But one has to learn how to conquer that. We have enough tenacity in us to conquer any difficut situation, said Pastor Roach.

Now we take a look a Michelle Keating a health care provider. a phenomenal women and volunteer with the St. Louis Gateway Area Chapter of Multiple Sclerosis. Keating says the diagnosis changed his life forever. Together they both have learned to adjust in different ways as MS affects what they can do .My first reaction was of denial and worry , what would my future be like?But my future has been very beautiful. I have two children I have raised and I continue my career as a nurse and wife.

Multiple sclerosis (MS) is a potentially debilitating disease in which your bodys immune system eats away at the protective sheath that covers your nerves. This interferes with the communication between your brain and the rest of your body. Ultimately, this may result in deterioration of the nerves themselves, a process thats not reversible.

Symptoms vary widely, depending on the amount of damage and which nerves are affected. People with severe cases of multiple sclerosis may lose the ability to walk or speak. Multiple sclerosis can be difficult to diagnose early in the course of the disease because symptoms often come and go sometimes disappearing for months.

Like anyone else in the MS movement, they actively volunteer and seek effective means to move closer to a world free of MS.

At this point theres no cure for multiple sclerosis. If you would like to join the movement with over 3,000 other cyclists riding towards a world free of MS, you can team up for the Bike MS Gateway Getaway Ride September 8&9 2012 in Columbia Missouri.

Visit link:
Fighting Back -Ordinary People Battling The Everyday Effects Of MS

ScienceDaily (Sep. 13, 2012) Many people with multiple sclerosis for years have taken the natural supplement Gingko biloba, believing it helps them with cognitive problems associated with the disease.

But the science now says otherwise. A new study published in the journal Neurology says Gingko biloba does not improve cognitive performance in people with multiple sclerosis. The research was published in the Sept. 5, 2012, issue of Neurology, the medical journal of the American Academy of Neurology. The current study was a more extensive look at the question after a smaller 2005 pilot study suggested there might have been some cognitive benefits in MS patients using the supplement. That study found that Gingko seemed to improve attention in MS patients with cognitive impairment.

But the larger follow-up study, conducted with patients at the Portland and Seattle Veterans Affairs medical centers, found no cognitive benefits to using Gingko.

"It's important for scientists to continue to analyze what might help people with cognitive issues relating to their MS," said Jesus Lovera, M.D., the study's lead author, a former fellow at the Portland VA Medical Center and former instructor in Oregon Health & Science University's Department of Neurology, where he did much of the work on the study. Lovera is now with the Department of Neurology at the Louisiana State University Health Sciences Center.

"We wanted to follow up on the earlier findings that suggested there may be some benefit. But we believe this larger study settles the question: Gingko simply doesn't improve cognitive performance with MS patients," said Lovera.

About one-half of people with MS will develop cognitive problems, and those cognitive problems can be debilitating in some people, said Dennis Bourdette, M.D., a co-author of the study, co-director of the VA MS Center of Excellence-West at the Portland VA Medical Center and chairman of the OHSU Department of Neurology. The most common problems relate to memory, attention and concentration, and information processing.

There is no known treatment that can improve cognition with MS patients -- which is partly why MS patients and researchers had hoped that Gingko biloba could help.

Lovera was also the lead author in the 2005 study, conducted at OHSU. That study included 39 participants who were given Gingko biloba or a placebo. The new study included 120 participants given Gingko or a placebo.

The study was supported by a grant from the U.S. Department of Veterans Affairs Rehabilitation Research and Development Service.

Share this story on Facebook, Twitter, and Google:

Here is the original post:
Gingko biloba does not improve cognition in multiple sclerosis patients, study finds

For each Teen BurgerTM sold in Canada , $1 will be given to the MS Society

MONTREAL , Aug. 20, 2012 /CNW Telbec/ - For a fourth consecutive year, the Multiple Sclerosis Society of Canada invites Quebecers to join the fight against MS as part of its annual fundraising and awareness event, in collaboration with A&W Food Services of Canada Inc. (AW-UN.TO).

How can I contribute?

Exclusively on Thursday, August 23 , for each Teen Burger sold across the country, one dollar will be donated to help fight MS. The A&W Rendez-vous event will also feature several fundraising activities in participating restaurants, including games, raffles, prizes and even personal appearances by the Great Root Bear himself! Well-known personality Patricia Paquin will be at the Plateau-Mont-Royal A&W restaurant, located at 4501 St-Denis Street, between 11:30 a.m. and 1 p.m.

Furthermore, until August 23:

"The A&W Rendez-vous to end MS campaign greatly contributes to financing ongoing MS cause and treatment research, as well as services offered to Canadians suffering from this illness, which is diagnosed in three Canadians per day, explains Yves Savoie, President and CEO, MS Society of Canada . We are very grateful toward all donors, as well as A&W guests and employees, for the active role they play year after year to ensure that this important fundraising event is a resounding success."

Canada posts one of the world's highest multiple sclerosis incidence rates. Indeed, an estimated one out of every two Canadians knows someone suffering from MS, and approximately 50,000 to 75,000 Canadians are currently fighting this disease. Of this figure, nearly 20,000 live in Qubec. While the cause of this often debilitating illness remains unknown, researchers are getting closer to a solution. The MS Society of Canada , the foremost organization in MS research, funds services to those suffering from MS and their families.

"In three years, A&W guests, employees and franchisees have raised over two million dollars to help fight MS, said Paul Hollands , President and CEO, A&W Food Services of Canada Inc. We're thrilled by this success and invite everyone to help make this incredible feat a reality by participating in the A&W Rendez-vous to end MS on August 23."

About multiple sclerosis and the MS Society of Canada Multiple sclerosis is a chronic, often disabling disease of the brain and spinal cord. It is the most common neurological disease of young adults in Canada . Most people with MS are diagnosed between the ages of 15 and 40, and the unpredictable effects of MS last for the rest of their lives. The MS Society provides services to people with MS and their families and funds research to find the cause and cure for this disease. Please visit mssociety.ca or call 1800 268-7582 to make a donation or for more information.

A&W Food Service of Canada Inc. is a purely Canadian company and one of the most recognized brands within the Canadian food service industry. A&W is the country's second largest hamburger restaurant chains, operating 730 locations across Canada . A&W restaurants offer their famous menu, which includes the Burger FamilyTM, Chubby ChickenTM and A&W Root BeerTM. For more information, please visit http://www.aw.ca.

Follow this link:
/R E P E A T -- A&W Rendez-vous to end MS: On Thursday, August 23, join Patricia Paquin and the Multiple Sclerosis ...

Multiple sclerosis is a prevalent disease that affects about 250,000 to 350,000 Americans, according to the National Institute of Health. This disease afflicts the brain and spinal cord, which make up the central nervous system, and causes the inflammation of the meninges, a lining of cells that cover the surface of the brain.

Though this is, as yet, an incurable disease, MS has many treatment and therapeutic options for patients. A group of Wayne State researchers, along with colleagues in Canada, have found a possible pathway that leads to disease progression which could lead to new therapies for patients.

WSU School of Medicine neurology associate chair and professor Joyce A. Benjamins, neurology professor Robert P. Lisak, neurology and immunology & microbiology assistant professor Samia Ragheba, neurology research assistants Liljana Nedelkoskaa and Jennifer Barger all contributed to the study.

The main idea behind the study was to see if B cells from patients with MS make substances that could be secreted that could damage CNS cells, Lisak said.

B cells are a type of lymphocytes, or white blood cells, that produce antibodies, which help the body in immune responses. In patients with multiple sclerosis, however, the B cells produce molecules that damage oligodendrocytes, which make myelin, Lisak said.

Myelin is a type of insulation for the axons of the nerve cells, neurons, in the CNS. If these protective coats are damaged and degraded, chemical communication between the brain and the rest of the body will be halted. Therefore, body movements such as walking, talking or bladder and bowel control are greatly hindered.

Benjamins said damage is not only done to the myelin sheath, but also to the neurons in a region of the brain called gray matter due to the dense population of neurons. Areas of gray matter are also called the cerebral cortex, and it is seen that damage in this area occurs early in the progression of the disease. The experiment to investigate B cells was conducted with the help of Canadian counterparts, Lisak said.

Our collaborators in Montreal isolated and cultured B cells from the blood of seven patients with MS and four healthy individuals, Lisak said.

The liquid from the cultures was sent to WSU where it was put in CNS culture. By analyzing the results, researchers found that the liquid from the B cells of MS patients killed oligodendrocytes, but not from the liquid of normal individuals.

This lead to the researchers conclusion that MS patients B cells secrete some sort of molecules or substances that directly attack CNS cells. These results are quite relevant and important for the study of progression. Lisak said these results show a new way through which B cells can damage neurons in MS; this novel pathway can lead the direction of how future therapies and treatment target the disease.

The rest is here:
Multiple sclerosis breakthrough raises hope for improved therapies

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/2z54ns/therapy_trends_mu) has announced the addition of the "Therapy Trends: Multiple Sclerosis" report to their offering.

On the cusp of a treatment revolution

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution

The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi's Aubagio and Genzyme's Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world's leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.

- We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time

Read the original post:
Research and Markets: Therapy Trends: Multiple Sclerosis

TWIN FALLS Bed racing in downtown Twin Falls is a crazy sight, but its meant to call attention to multiple sclerosis, an illness with devastating effects.

Judy and John Fisher organize an annual Bed Race fundraiser, now in its third year, to support MS research. Five-person teams will race downtown June 16, and its time to prepare your bed and polish your racing technique.

It started as a wild idea of a way to raise money, John said. We make more money this way than by walking.

While the Twin Falls couple still participates in a multiple sclerosis walk, John said, their fundraising from the Bed Race grew from $500 the first year to $3,000 last year.

Besides the main event, raffle prizes will include visits to Lagoon, Roaring Springs, Cactus Petes Resort Casino and Silver City.

Each year weve had a better turnout and weve had a lot of good help and sponsors, said Judy, who has MS. Which is great because people dont seem to realize how serious the illness is.

David Elgan of Jerome is an example of how the illness can change the course of a life. Elgans military career with the National Guard was squashed after his diagnosis in 2010.

The pain in my feet was so bad I couldnt run, Elgan said. I wish more people knew what MS is and what its all about. This disease takes away your life.

Elgan is trying to assemble a team for the races but said it will be a last-minute feat if it comes together.

Ive never laughed so much in my life, Elgan said of watching last years races.

See the article here:
Prep Your Bed for Multiple Sclerosis

Yesterday was World MS Day, designated to raise awareness about multiple sclerosis. Sanofi launched a program to mobilize and inspire people with MS called Everyday Matters. Biogen Idec, among other things, conducted an essay competition in Japan for stories from people living with MS. Acorda Therapeutics (Nasdaq: ACOR) launched an online talk show.

Cute marketing gimmicks -- especially the talk show -- but in the big picture, none of it matters all that much for sales. Ultimately, efficacy and safety will rule.

CRABs Teva Pharmaceuticals' (Nasdaq: TEVA) Copaxone, Rebif -- marketed by Pfizer (NYSE: PFE) and Merck KgaA -- Biogen's Avonex, and Bayer's Betaseron are the oldies-but-goodies for multiple sclerosis. They're not exceptionally effective -- they certainly don't cure MS -- but doctors will continue to use them because they do delay the progression of MS and doctors have lots of experience with them.

We should throw Novartis' (NYSE: NVS) Extavia into the mix here since it's the same drug as Betaseron sold under a different label after each pharma bought the biotechs that had rights to Betaseron.

Stratifying riskBiogen and Elan's (NYSE: ELN) Tysabri works better than the older medications, but it has a distinct disadvantage: the potential for an often-fatal brain infection called progressive multifocal leukoencephalopathy, or PML.

Tysabri doesn't cause PML directly. That honor goes to the JC virus. Tysabri just helps the normally harmless virus do its dirty work. While keeping the immune system from attacking the patient's own cells, Tysabri also discourages the immune system from attacking the JC virus.

The JC virus is present in about half of patients. If it isn't floating around dormant in the body, it can't cause PML. So Biogen and Elan developed an assay to detect the JC virus. The assay has only been on the market for a short time, but it seems to be helping the companies capture patients earlier in their disease progression, which should help increase sales.

Needle-freeThe second generation of multiple sclerosis drugs are taken orally. Novartis' Gilenya was the first on the market, but it hasn't been a hot seller because of safety concerns.

Biogen's BG-12, Teva's laquinimod, and Sanofi's teriflunomide have all completed phase 3 trials, and it looks like BG-12 is the winner. Biogen recently submitted the drug to the Food and Drug Administration, so a decision should be made near the end of the year.

Like Gilenya, I'd expect BG-12 to have a slow start. MS is a progressive disease that isn't immediately life-threatening for most patients, so there's little reason for most patients to be guinea pigs. Doctors will likely start with patients that have a strong aversion to needles to get a feel for the drug before prescribing it to a wider audience.

Originally posted here:
Big Bets on MS

Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech recently announced that they intend to commence a phase III study with their oral multiple sclerosis candidate, laquinimod. The study will be conducted under the US Food and Drug Administrations (:FDA) Special Protocol Assessment (SPA) program.

The phase III study, CONCERTO, will be conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study for up to 24 months with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (:EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohns disease and lupus.

The successful development and launch of laquinimod would help strengthen Tevas multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio Copaxone. Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Teva received some good news on the Copaxone patent infringement lawsuit front recently with favorable court rulings in the UK and the US. With these rulings, Copaxone should be protected from generic competition until September 2015.

The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxones life cycle.

We are pleased with Tevas efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US. Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen (BIIB) and Novartis (NVS) among others.

We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term Hold rating).

The rest is here:
Update on Teva's Laquinimod